—
title: “CE-IVD and FDA 510(k) Regulatory Pathways for POCT Diagnostic Devices”
—
## Abstract
Navigating regulatory requirements is essential for global market access of **lateral flow strips** and POCT devices. This guide from experienced **POCT manufacturer** Due Bio outlines CE-IVD marking and FDA 510(k) clearance pathways for **IVD Reagents OEM/ODM** partners targeting European and US markets.
## Introduction
Regulatory compliance determines market eligibility for in vitro diagnostic devices. The European Union’s IVDR (2017/746) and US FDA’s 510(k) premarket notification require comprehensive technical documentation, clinical evidence, and quality system certification. This application note summarizes key requirements based on 35+ years of regulatory experience since 1987.
## Materials Required
– Technical File / Design Dossier documentation
– Clinical performance study reports
– Risk management file (ISO 14971)
– Quality Management System certificate (ISO 13485)
– Essential Principles checklist
– Labeling and IFU (Instructions for Use)
– Post-market surveillance plan
## Step-by-Step Protocol
1. **Device Classification**: Determine risk class (EU: Class A/B/C/D; US: Class I/II/III). Most **lateral flow** rapid tests fall under Class B (EU) or Class II (US) requiring Notified Body or FDA review.
2. **Technical Documentation**: Compile comprehensive Technical File including device description, intended use, design verification/validation, biocompatibility, and software validation (if applicable).
3. **Clinical Evidence**: Conduct performance studies with minimum 200-500 clinical samples comparing against predicate devices or reference methods. Document sensitivity, specificity, and agreement statistics.
4. **Quality System Audit**: Obtain ISO 13485 certification through accredited registrar. FDA requires QSR (21 CFR 820) compliance for US market entry.
5. **Submission and Review**: Submit CE Technical File to Notified Body or FDA 510(k) premarket notification. Respond to deficiency letters within specified timelines (typically 30-90 days).
## Troubleshooting
**Q: Notified Body requests additional clinical data.**
A: Plan for expanded clinical studies during product development. Include diverse patient populations and clinically relevant sample types to strengthen evidence package.
**Q: FDA identifies substantial differences from predicate device.**
A: Consider alternative predicate or prepare for de novo classification. Engage FDA through Q-Submission program for early feedback on regulatory strategy.
**Q: IVDR transition timeline creates market access gaps.**
A: Prioritize Class C/D products for IVDR compliance. Leverage MDR transitional provisions where applicable. Maintain parallel CE and FDA submissions for global launch.
## Conclusion & OEM/ODM Partnership
Regulatory expertise accelerates time-to-market for **POCT** diagnostics. Due Bio, established in **1987**, offers comprehensive regulatory support for **OEM/ODM** partners including Technical File preparation, clinical study design, and Notified Body liaison services.
**Contact**: medtiger@foxmail.com for regulatory strategy consultation and compliance support.
**Keywords**: POCT manufacturer, lateral flow strips, IVD Reagents OEM/ODM, CE-IVD, FDA 510(k), IVDR, regulatory affairs, ISO 13485